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Distribution of plasma folate forms in hemodialysis patients Elevation of plasma total homocysteine (tHcy) is ob-
receiving high daily doses of L-folinic or folic acid. served in at least 85% of patients with end-stage renal
Background. We have previously reported that a daily oral disease (ESRD) undergoing maintenance hemodialysis [1].high dose of l-folinic acid for the treatment of hyperhomo-
Several attempts have been made to lower the plasmacysteinemia in hemodialysis patients does not provide signifi-
tHcy levels in hemodialysis patients. For example, ourcantly greater reduction in fasting total homocysteine (tHcy)
levels than an equimolar dose of folic acid. The present study previous study showed that a final treatment value of
uses the affinity/HPLC method to analyze the distribution of plasma tHcy 12 mol/L was achieved in only one of 15
plasma folate forms in patients who received l-folinic acid (6.7%) dialysis patients despite two months of supple-versus those who received folic acid. This was done to investi-
mentation with a total of 16 mg per day of folic (pteroy-gate claims that renal insufficiency is associated with impaired
folate interconversion, a stance that is supportive of the premise glutamic) acid, 50 mg per day of vitamin B6, and 1 mg
that tHcy lowering in these patients is more efficacious with per day of vitamin B12 [2].
folinic acid and other reduced folates, than folic acid. In an open-label, uncontrolled investigation, Touam
Methods. Forty-eight chronic and stable hemodialysis pa-
et al concluded that high doses of the reduced folatetients were block-randomized, based on their screening predial-
l–5-formyltetrahydrofolate (l-folinic acid) might pro-ysis tHcy levels, sex, and dialysis center, into two groups treated
for 12 weeks with oral folic acid at 15 mg/day or an equimolar vide improved tHcy-lowering efficacy in patients with
amount (20 mg/day) of oral l-folinic acid. All 48 subjects also ESRD undergoing maintenance hemodialysis [3]. We
received 50 mg/day of oral vitamin B6 and 1 mg/day of oral recently reported results from a randomized controlledvitamin B12. Folate distribution was determined in plasma of 46
trial comparing the tHcy-lowering efficacy of equimolarparticipants (Folinic acid group, N 22; Folic acid group, N
24) by using the affinity/HPLC method, with electrochemical amount of l-5-methytetrahydofolate (17 mg/day) versus
(coulometric) detection. folic acid (15 mg/day)-based B vitamin supplementation
Results. Both groups had similar baseline geometric means in 50 (that is, two matched groups of 25) hemodialysisof plasma total folate and similar folate forms distribution.
patients. After 12 weeks of treatment, the mean percent-Following treatment, both groups demonstrated similar marked
age reductions in predialysis tHcy were not significantlyelevation in plasma total folate (geometric mean of the in-
crease: Folinic acid group,337 ng/mL; Folic acid group,312 different (l-5-methytetrahydofolate group, 17%; Folic
ng/mL; P 0.796). In the folinic acid-treated group, practically acid group, 14.8%; P  0.444) [4]. We also conducted a
all of the increase in total folate was due to 5-methyltetrahy- block randomized, controlled comparison of oral treat-drofolate. In the folic acid-treated group 5-methyltetrahydrofo-
ment with either high-dose l-folinic acid or folic acid,late accounted for 35% of the increase in total folate and the
remainder was unmethylated folic acid. combined with oral vitamin B6 and vitamin B12, in 48 (that
Conclusions. Data from the present findings suggest that is, two matched groups of 24) maintenance hemodialysis
defects in folate absorption or impairment in folate intercon- patients. Relative to the high dose of folic acid, high-doseversion are not the cause of the persistent hyperhomocysteine-
oral l-folinic acid–based B vitamin supplementation didmia in hemodialysis patients.
not improve the tHcy-lowering efficacy in hemodialysis
patients. Final post-treatment tHcy mean values (with
Key words: end-stage renal disease, homocysteine, maintenance hemo-
95% CI) were: Folinic acid group, 15.9 mol/L (22.1%dialysis, hyperhomocysteinemia, 5-methyltetrahydrofolate, pteroyglu-
tamic acid. decrease); Folic acid group, 16.9 mol/L (20.7% de-
crease; P  0.950) [5]. The present study used our newlyReceived for publication February 7, 2002
developed affinity/high-pressure liquid chromatographyand in revised form May 8, 2002
Accepted for publication July 11, 2002 (HPLC) method [6] to analyze plasma folate forms distri-
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of l-folinic acid versus those receiving folic acid. Our separates folates both on the basis of their pteridine
ring structure and number of glutamate residues. Folategoal in the current study was to assess, as suggested by
certain investigations [7–11], whether the metabolism of forms elute in the following order: tetrahydrofolate (THF);
5-methylTHF; 5,10-methyleneTHF, 5- and 10-formylTHF;supplemented folic acid to 5-methyltetrahydrofolate is
impaired in hemodialysis patients. dihydrofolate; and pteroyglutamate. Folate activity is de-
termined by using an ESA Four Channel Coularray De-
tector (ESA, Chelmsford, MA, USA) with channels 1
METHODS
to 4 set at 0, 300, 500 and 600 mV, respectively. Quantifi-
Plasma was analyzed from 46 hemodialysis patients cation and identification of individual folates was done
who participated in a study described previously [5]. by comparison to external folate standards of known
Briefly, participants comprised 48 chronic (that is, hemo- concentration. The coefficient of variations (CVs) for
dialysis duration6 months) stable hemodialysis paients folate detection (4 to 30 ng/mL) by the described method
who were prescribed a daily multivitamin that contained ranged between 0.6 and 6.4% (intra-assay) and 5.2 and
1.0 mg folic acid, 10.0 mg vitamin B6, and 0.012 mg 8.4% (interassay). This variation included the duplicate
vitamin B12. This baseline supplementation regimen was samples taken before and after treatment.
continued throughout the 12-week investigation. Partici-
pants were randomly assigned in paired blocks to one of Statistical analysis
two treatment regimens: (1) Folic acid group (N  24) All values reported are based on average of two pre-
prescribed folic acid 15.0 mg/day, vitamin B6 50.0 mg/ treatment and post-treatment values. Baseline continu-
day, and vitamin B12 1.0 mg/day; and (2) Folinic acid ous variables were compared by paired t tests, and cate-
group (N  24) prescribed l-5-formyltetrahydrofolate gorical variables were compared by chi square analysis.
20.0 mg/day (that is, equimolar to 15.0 mg/day folic acid; Continuous variables were assessed using both untrans-
Eprova, Zurich, Switzerland); vitamin B6 50.0 mg/day; formed and (natural log) transformed values. Reported
and vitamin B12, 1.0 mg/day. Nonfasting, prehemodialysis P values were based on two tailed calculations. Differ-
blood samples were collected twice before treatment and ences were considered to be significant if P  0.05. All
twice during the 12th week of treatment, as described statistical analyses were performed using SYSTAT soft-
elsewhere [5]. All reported values are based on the aver- ware (version 10.0; SPSS, Chicago, IL, USA).
ages of two pretreatment and post-treatment values.
Laboratory analyses, data entry and data analyses were
RESULTSperformed by code so that treatment assignments re-
The block randomization of this study was successfulmained concealed.
with respect to the key baseline covariables [5]. Plasma
Plasma folate analysis folate distribution analyses revealed that both 5-methyl-
tetrahydrofolate and pteroyglutamate were the main fo-The plasma folate forms distribution of 46 participants
(Folinic acid group, N  22; Folic acid group, N  24) late forms present in plasma of all patients. Figure 1
represents typical chromatograms of folate distributionwas determined using our newly devised affinity/HPLC
method with electrochemical (coulometric) detection [6]. before and after treatment for each group. Analysis of
baseline plasma folate distribution in the 46 patients isPlasma was diluted tenfold with extraction buffer (0.05
mol/L potassium tetraborate, 1% sodium ascorbate, pH summarized according to treatment group in Table 1.
Both groups had a similar baseline geometric mean of9.2), heat extracted (100C for 15 min) and centrifuged
for 15 minutes at 36,000 g. Two milliliters of the super- total plasma folate (Folinic acid group, 43.2 0.4 ng/mL;
Folic acid group, 31.1  0.5 ng/mL; P  0.207), andnatant fraction was injected onto the affinity column
(10 4.6 mm) that contained purified milk folate binding similar folate forms distribution (5-methyltetrahydrofo-
late: Folinic acid group, 33.1 0.4 ng/mL, Folic acid group,protein covalently bound to AffiPrep 10 support (Bio-
Rad, Richmond, CA, USA). After washing the affinity 26  0.4 ng/mL, P  0.295; Folic acid: Folinic acid group,
5  0.8 ng/mL, Folic acid group, 4.7  0.8 ng/mL, P column sequentially with 0.05 mol/L potassium phosphate,
pH 7, and water the folates were eluted onto the analyti- 0.908). Following treatment both groups demonstrated
a similar marked elevation in plasma total folate (geo-cal column (Betasil Phenyl, 250  4.6 mm; Keystone
Scientific, Bellefonte, PA, USA) with an acid mobile metric mean of the increase: Folinic acid group, 337
ng/mL; Folic acid group, 312 ng/mL; P  0.796; Tablephase (0.028 mol/L dipotassium phosphate and 0.06 mol/L
phosphoric acid in water). Folates then were eluted from 2). In the folinic acid group 96% of this increase was
accounted by 5-methyltetrahydrofolate. In the folic acidthe analytical column by using the same aqueous mobile
phase at a flow rate of 1 mL/min for six minutes followed group 35% of the increase in total folate was due to
5-methyltetrahydrofolate, the rest being unmethylatedby a linear gradient over 50 minutes to the same mobile
phase containing 20% acetonitrile (vol/vol). This elution folic acid.
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Fig. 1. Representative chromatograms of folate forms distribution. All panels show the electrochemical response of channels 1, 2, 3 and 4 set at
0, 300, 500 and 600 mV, respectively. Panels (A) and (B) represent plasma folate distribution for the folinic acid group before and after treatment,
respectively. Panels (C) and (D) represent plasma folate distribution for the folic acid group before and after treatment, respectively. In both
groups, plasma samples obtained after treatment (B and D) were diluted 1:5 with 1% sodium ascorbate before HPLC analysis. Abbreviations are:
M, 5-methyltetrahydrofolate; PG, folic acid (pteroyglutamate); The number after the abbreviation indicates the number of glutamate residues.
Table 2. Treatment effects on folate forms distributionTable 1. Baseline folate forms distribution by treatment group
Folate distribution Folate distribution
% of the increase% of total folates
Total folates Total folates
Treatment group ng/mL MTHF PteGluTreatment group ng/mL MTHF a PteGlua
Folic acid 31.10.5 (20.7–46.7) 83.6% 15.1% Folic acid 312.6 (160–613) 35%a 70%a
Folinic acid 337.8 (214–532) 96% 2%Folinic acid 43.20.4 (30.6–60.8) 76.6% 11.5%
Values are geometric means of the increase (with 95% CI) for total folate,Values are geometric means  SE (with 95% CI) for total folate, and %
of 5-methyltetrahydrofolate (MTHF) and pteroyglutamate (PteGlu) from total and % of MTHF and PteGlu from the increase of total folate. Abbreviations are:
MTHF, 5-methyltetrahydrofolate; PteGlu, pteroyglutamate. Treatment groupsfolate.
a Differences are not significant between the two groups were: (1) Folic acid, 15 mg folic acid, 50 mg vitamin B6, and 1.0 mg vitamin B12;
(2) Folinic acid, 20 mg l-folinic acid, 50 mg vitamin B6, and 1.0 mg vitamin B12.
a P  0.05 compared to folinic acid group within each folate form
DISCUSSION
5-methyltetrahydrofolate, the substrate for homocys-
The homocysteine lowering capacity of supplemental teine methylation to methionine [12]. The present study
folic acid lies in the propensity of enzymes within the shows that daily supplementation with high doses of folic
intestine and other peripheral tissues to catalyze the con- acid or folinic acid for 12 weeks resulted in two substan-
version of this vitamin to folate coenzymes. This includes tial changes in plasma folate. First, there was an almost
reduction to tetrahydrofolate and subsequent one carbon eight- to tenfold increase in the levels of total folate in
substitution, either at the formate (formyltetrahydro- plasma in either group. This large increase in total folate
folate) or at the formaldehyde (methylene-tetrahydro- refutes the notion that hemodialysis patients have im-
paired intestinal folate absorption [7–11].folate) levels of oxidation. These are then reduced to
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Department of Agriculture, nor does mention of trade names, commer-Second, a substantial proportion of this rise in plasma
cial products, or organization imply endorsement by the U.S. Govern-
folate was comprised of 5-methyltetrahydrofolate. This ment.
high level of 5-methyltetrahydrofolate strongly implies
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